|
市場調查報告書
產品簡介:上市抗菌藥 - 學名藥的增加，市場分化·混戰
Product Profiles: Marketed Antibacterials - Increasing genericization and fragmentation shape a crowded market
| 出版商 |
Datamonitor |
| 出版日期 |
2011年11月 |
商品編碼 |
229435 |
| 內容資訊 |
英文 Pages: 110 |
| 價格 |
|
|
產品簡介:上市抗菌藥 - 學名藥的增加，市場分化·混戰 是由出版商Datamonitor在2011年11月所出版的。
這份英文市場調查報告書包含Pages: 110 價格從美金11400起跳。
在過去兩年，包含Levaquin、Zosyn、Merrem在內的許多抗菌藥都失去了專利保護。今後的醫藥品由於學名藥流入市場，預計銷售額將被大幅侵食。
本報告提供上市抗菌藥(抗生素)市場相關調查，提供上市抗菌藥的臨床實驗資料概括性分析及臨床、商業性魅力評估，在分化地愈來愈細的市場上，為求成功的策略性機會分析，主要品牌的成功因素、新上市新藥的潛力等資料，為您概述為以下內容。
摘要整理
概要
產品概要
上市產品簡介
- Levaquin/Cravit/Tavanic (levofloxacin; Johnson & Johnson/第一三共/Sanofi)
- 製藥簡介
- 發展概要
- SWOT分析
- 產品定位
- 臨床及商業性魅力
- Zosyn/Tazocin (piperacillin/tazobactam; Pfizer/大正製藥)
- 製藥簡介
- 發展概要
- SWOT分析
- 產品定位
- 臨床及商業性魅力
- Zyvox (linezolid; Pfizer)
- 製藥簡介
- 發展概要
- SWOT分析
- 產品定位
- 臨床及商業性魅力
- Avelox/Octegra (moxifloxacin; Bayer/Merck & Co.)
- 製藥簡介
- 發展概要
- SWOT分析
- 產品定位
- 臨床及商業性魅力
- Cubicin (daptomycin; Cubist Pharmaceuticals/Novartis/Merck & Co.)
- 製藥簡介
- 發展概要
- SWOT分析
- 產品定位
- 臨床及商業性魅力
- Merrem/Meropen (meropenem; AstraZeneca/Dainippon Sumitomo Pharma)
- 製藥簡介
- 發展概要
- SWOT分析
- 產品定位
- 臨床及商業性魅力
- Tygacil (tigecycline; Pfizer)
- 製藥簡介
- 發展概要
- SWOT分析
- 產品定位
- 臨床及商業性魅力
- Vibativ (telavancin; Theravance/Astellas Pharma)
- 製藥簡介
- 發展概要
- SWOT分析
- 產品定位
- 臨床及商業性魅力
- 其他市售抗菌藥
參考文獻
附錄
圖表
Description
Introduction
In the last two years, several leading antibacterials lost patent protection, including broad-spectrum drugs Levaquin, Zosyn, and Merrem. Generic incursion will significantly erode future sales for these drugs. A number of strong competitors remain that still hold patent protection, but the majority only target Gram-positive pathogens, including methicillin-resistant Staphylococcus aureus (MRSA).
Features and benefits
- Comprehensive analysis of clinical trial data and assessment of clinical and commercial attractiveness for marketed antibacterials
- Discussion of future strategic opportunities to achieve success in an increasingly fragmented antibacterials market
Highlights
- Levaquin, the biggest-selling antibacterial globally garnering sales over $2.5bn in 2010, lost patent protection in 2011, constituting a major blow to the marketing partners Johnson & Johnson, Daiichi Sankyo and Sanofi. Datamonitor expects generic incursion to be very strong.
- Zyvox remains one of most successful drugs on the market to target Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA). Recent clinical trial data have strengthened its position as the drug of choice to treat Gram-positive nosocomial pneumonias, which may swing physician prescribing practices towards Zyvox.
- The anti-MRSA market will become increasingly crowded over the coming years, with the expected approval of several strong competitors. Drugs currently on the market in this sector will need to attempt to fill important treatment gaps by acquiring approval for further indications.
Your key questions answered
- Identify key drugs within the antibacterials market, success factors for leading brands, and the potential for new entrant products.
- Assess strengths, weaknesses, opportunities and threats of key marketed antibacterials and how they influence clinical and commercial attractiveness.
TOC
Executive Summary
- Strategic scoping and focus
- Datamonitor key findings
- Related reports
OVERVIEW
PRODUCT OVERVIEW
MARKETED PRODUCT PROFILES
- Levaquin/Cravit/Tavanic (levofloxacin; Johnson & Johnson/Daiichi Sankyo/Sanofi)
- Drug profile
- Development overview
- SWOT analysis
- Product positioning
- Clinical and commercial attractiveness
- Zosyn/Tazocin (piperacillin/tazobactam; Pfizer/Taisho Pharmaceutical)
- Drug profile
- Development overview
- SWOT analysis
- Product positioning
- Clinical and commercial attractiveness
- Zyvox (linezolid; Pfizer)
- Drug profile
- Development overview
- SWOT analysis
- Product positioning
- Clinical and commercial attractiveness
- Avelox/Octegra (moxifloxacin; Bayer/Merck & Co.)
- Drug profile
- Development overview
- SWOT analysis
- Product positioning
- Clinical and commercial attractiveness
- Cubicin (daptomycin; Cubist Pharmaceuticals/Novartis/Merck & Co.)
- Drug profile
- Development overview
- SWOT analysis
- Product positioning
- Clinical and commercial attractiveness
- Merrem/Meropen (meropenem; AstraZeneca/Dainippon Sumitomo Pharma)
- Drug profile
- Development overview
- SWOT analysis
- Product positioning
- Clinical and commercial attractiveness
- Tygacil (tigecycline; Pfizer)
- Drug profile
- Development overview
- SWOT analysis
- Product positioning
- Clinical and commercial attractiveness
- Vibativ (telavancin; Theravance/Astellas Pharma)
- Drug profile
- Development overview
- SWOT analysis
- Product positioning
- Clinical and commercial attractiveness
- Other marketed antibacterials
- Augmentin (amoxicillin/clavulanate acid; GlaxoSmithKline)
- Primaxin/Zienam/Tienam (imipenem/cilastatin; Merck & Co.)
- Biaxin/Klaricid/Clarith (clarithromycin; Taisho/Abbott)
- Zithromax/Zithromac (azithromycin; Pfizer)
BIBLIOGRAPHY
- Journal papers
- Websites
- Datamonitor reports
APPENDIX
- PharmaVitae Explorer database
- Contributing experts
- Conferences attended
- Report methodology
|
